Amgen Inc (AMGN)

171.14
0.30 0.18
NASDAQ : Health Care
Prev Close 170.84
Open 169.92
Day Low/High 169.08 / 170.66
52 Wk Low/High 130.09 / 176.64
Volume 397.81K
Avg Volume 2.90M
Exchange NASDAQ
Shares Outstanding 748.36M
Market Cap 130.51B
EPS 9.20
P/E Ratio 15.73
Div & Yield 4.00 (2.30%)

Latest News

New Data Add To Understanding Of Repatha® (Evolocumab) In Multiple Patient Populations

New Data Add To Understanding Of Repatha® (Evolocumab) In Multiple Patient Populations

11 Abstracts to be Presented at ESC Congress 2016

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.

Upcoming Must-Own Dates

Nineteen stocks with with upcoming must-own dates.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

Stocks Retreat From Records as Health Care Slumps

Stocks Retreat From Records as Health Care Slumps

Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.

Health Care Drags Stocks Away From Records

Health Care Drags Stocks Away From Records

Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Stocks secure robust gains after the latest labor market snapshot breezes past expectations.

Biogen Is a Takeover Target but Don't Ignore the Risks

Biogen Is a Takeover Target but Don't Ignore the Risks

The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

Amgen and Regeneron Expanding Anti-Cancer Research

Amgen and Regeneron Expanding Anti-Cancer Research

The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts

Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts

The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.

Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration

Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration

Collaboration Will Advance Highly Targeted, Patient-Specific Treatment Approach

Can Amgen Break Out?

The company has pushed to the top of a large consolidation pattern.

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Here's When You Should Buy Amgen

Here's When You Should Buy Amgen

A healthy pullback in Amgen would create a low-risk buying opportunity.

Amgen (AMGN) Stock Higher After Q2 Results, Raised Forecast

Amgen (AMGN) Stock Higher After Q2 Results, Raised Forecast

Amgen (AMGN) stock is up on Thursday afternoon following the company’s solid earnings and revenue results for the 2016 second quarter, and upbeat guidance.

Facebook Blows Away Estimates, Stock Soars to All-Time High

Facebook Blows Away Estimates, Stock Soars to All-Time High

Facebook (FB) smashed earnings expectations--again. Shares are hitting record highs in the pre-market.

Market Ends Weak as Rate Hike Put Off: See You in September?

Market Ends Weak as Rate Hike Put Off: See You in September?

Stocks remain very unconcerned about rates, despite the odds of a fall increase slightly rising.

Amgen (AMGN) Stock Down in After-Hours Trading Despite Q2 Earnings Beat, Positive Guidance

Amgen (AMGN) Stock Down in After-Hours Trading Despite Q2 Earnings Beat, Positive Guidance

Amgen (AMGN) reported 2016 second quarter earnings after the closing bell today that beat analysts' expectations.

3 Drugs Stocks Pushing Industry Growth

3 Drugs Stocks Pushing Industry Growth

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Amgen Still Has Many Ways to Win

Amgen Still Has Many Ways to Win

Amgen investors have had a rough ride. The stock is down about 3% year to date, but the second half of the year could get interesting.

'Mad Money' Lightning Round: Why Isn't Taser's Stock Higher?

'Mad Money' Lightning Round: Why Isn't Taser's Stock Higher?

Cramer is no fan of Chesapeake Energy and thinks Gartner has great growth.

Jim Cramer's 'Mad Money' Recap: Verizon Is Building a Digital Empire

Jim Cramer's 'Mad Money' Recap: Verizon Is Building a Digital Empire

Buying Yahoo!'s core assets is the start of something very big, Cramer says.